RU2005118750A - Органические соединения - Google Patents
Органические соединения Download PDFInfo
- Publication number
- RU2005118750A RU2005118750A RU2005118750/14A RU2005118750A RU2005118750A RU 2005118750 A RU2005118750 A RU 2005118750A RU 2005118750/14 A RU2005118750/14 A RU 2005118750/14A RU 2005118750 A RU2005118750 A RU 2005118750A RU 2005118750 A RU2005118750 A RU 2005118750A
- Authority
- RU
- Russia
- Prior art keywords
- aneurysm
- increased
- pimecrolimus
- hollow tubes
- stent
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 206010002329 Aneurysm Diseases 0.000 claims 15
- 230000001965 increasing effect Effects 0.000 claims 10
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 8
- 229960005330 pimecrolimus Drugs 0.000 claims 8
- 230000006641 stabilisation Effects 0.000 claims 6
- 238000011105 stabilization Methods 0.000 claims 6
- 230000015556 catabolic process Effects 0.000 claims 4
- 238000006731 degradation reaction Methods 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 208000035868 Vascular inflammations Diseases 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 2
- 208000024248 Vascular System injury Diseases 0.000 claims 2
- 208000012339 Vascular injury Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 230000003628 erosive effect Effects 0.000 claims 2
- 210000002744 extracellular matrix Anatomy 0.000 claims 2
- 230000008595 infiltration Effects 0.000 claims 2
- 238000001764 infiltration Methods 0.000 claims 2
- 210000004969 inflammatory cell Anatomy 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 2
- 230000008719 thickening Effects 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042434 Sudden death Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000010339 dilation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/22—Eight-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Claims (8)
1. Устройство или система для доставки лекарственного вещества, включающая а) медицинское приспособление, адаптированное для местного применения или введения в полые трубки, и в сочетании с б) терапевтической дозой пимекролимуса в свободной форме или в форме фармацевтически приемлемой соли.
2. Устройство или система по п.1, где медицинским приспособлением является катетерное приспособление для доставки, адаптированное для местного применения или введения в полые трубки.
3. Устройство или система по п.1, где медицинским приспособлением является катетерное приспособление для доставки, приспособление или система местной инъекции, внутрипросветное или постоянное приспособление, адаптированное для местного применения или введения в полые трубки, стент, стент с нанесенным покрытием, внутрипросветная муфта, стент-трансплантат, матрица с контролируемым высвобождением, полимерное или биологическое внутрипросветное покрытие или адвентициальная манжета.
4. Устройство или система по п.1, где пимекролимус присоединен к медицинскому приспособлению способом, допускающим высвобождение лекарственного вещества.
5. Устройство или система по п.1, которая включает стент с нанесенным покрытием.
6. Применение пимекролимуса в свободной форме или в форме фармацевтически приемлемой соли при получении лекарственного средства для предупреждения и лечения воспалительных осложнений после сосудистой травмы, такого предупреждения и лечения, как предупреждение или лечение сосудистого воспаления или пролиферации и миграции клеток гладкой мышцы, или расширения аневризмы в полых трубках, или повышенной деградации и эрозии внеклеточного матрикса в полых трубках, или повышенной инфильтрации воспалительных клеток, или повышенной клеточной пролиферации, или сниженного апоптоза, или повышенного отложения или деградации матрикса, или повышенной положительной коррекции аневризмы (дилатации аневризмы) после размещения приспособления; или лечение утолщения интимы или расширение аневризмы в сосудистых стенках; или стабилизация атеросклеротических бляшек, или стабилизация участков аневризмы; или стабилизация или снижение дилатации аневризмы в участке аневризмы.
7. Способ лечения воспалительных осложнений после сосудистой травмы, такой, как для предупреждения или лечения сосудистого воспаления или пролиферации и миграции клеток гладкой мышцы или расширения аневризмы в полых трубках, или повышенной деградации и эрозии внеклеточного матрикса в полых трубках, или повышенной инфильтрации воспалительных клеток, или повышенной клеточной пролиферации, или сниженного апоптоза, или повышенного отложения или деградации матрикса, или повышенной положительной коррекции аневризмы (дилатации аневризмы) после размещения устройства у нуждающегося в этом млекопитающего, включающего введение терапевтически эффективно количества пимекролимуса; лечения утолщения интимы или расширения аневризмы в сосудистых стенках у нуждающегося в этом млекопитающего, включающего контролируемую доставку терапевтически эффективного количества пимекролимуса с помощью катетерного или внутрипросветного медицинского приспособления; стабилизации атеросклеротических бляшек или стабилизации участков аневризмы, или стабилизации либо уменьшения дилатации аневризмы в участке аневризмы у нуждающегося в этом млекопитающего, включающей введение терапевтически эффективного количества пимекролимуса; необязательно вместе с одним или несколькими другими активными ингредиентами; в соответствии с которым пимекролимус используют в свободной форме или в форме фармацевтически приемлемой соли.
8. Способ по п.7, в котором основным состоянием, на которое оказывают благоприятное воздействие, является стеноз, рестеноз, сосудистое воспаление, тромбоз, нестабильная стенокардия, инфаркт миокарда, сердечная недостаточность, ишемия, внезапная смерть, инсульт и/или разрыв аневризмы, причем пимекролимус вводят из стента или из покрытия, нанесенного на стент, или вводят в сочетании со стентом.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42680902P | 2002-11-15 | 2002-11-15 | |
| US60/426,809 | 2002-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005118750A true RU2005118750A (ru) | 2006-03-20 |
Family
ID=32326430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005118750/14A RU2005118750A (ru) | 2002-11-15 | 2003-11-14 | Органические соединения |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060035879A1 (ru) |
| EP (1) | EP1585738A2 (ru) |
| JP (1) | JP2006522007A (ru) |
| KR (1) | KR20050086648A (ru) |
| CN (1) | CN1714085A (ru) |
| AU (1) | AU2003283399B2 (ru) |
| BR (1) | BR0316279A (ru) |
| CA (1) | CA2511573A1 (ru) |
| CO (1) | CO5690530A2 (ru) |
| EC (1) | ECSP055788A (ru) |
| MX (1) | MXPA05005196A (ru) |
| NO (1) | NO20052898L (ru) |
| NZ (1) | NZ539850A (ru) |
| PL (1) | PL376169A1 (ru) |
| RU (1) | RU2005118750A (ru) |
| WO (1) | WO2004045578A2 (ru) |
| ZA (1) | ZA200503502B (ru) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
| US7208011B2 (en) * | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
| HK1042251B (en) | 1999-01-13 | 2012-07-20 | Bayer Healthcare Llc | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
| US7056338B2 (en) * | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| US7758636B2 (en) * | 2002-09-20 | 2010-07-20 | Innovational Holdings Llc | Expandable medical device with openings for delivery of multiple beneficial agents |
| CA2505576A1 (en) * | 2002-11-08 | 2004-05-27 | Conor Medsystems, Inc. | Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor |
| US20040202692A1 (en) * | 2003-03-28 | 2004-10-14 | Conor Medsystems, Inc. | Implantable medical device and method for in situ selective modulation of agent delivery |
| AU2004226327A1 (en) | 2003-03-28 | 2004-10-14 | Innovational Holdings, Llc | Implantable medical device with beneficial agent concentration gradient |
| US20040254629A1 (en) * | 2003-04-25 | 2004-12-16 | Brian Fernandes | Methods and apparatus for treatment of aneurysmal tissue |
| PT1626714E (pt) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
| DE602004010407T2 (de) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden |
| US20050033417A1 (en) * | 2003-07-31 | 2005-02-10 | John Borges | Coating for controlled release of a therapeutic agent |
| US20050100577A1 (en) * | 2003-11-10 | 2005-05-12 | Parker Theodore L. | Expandable medical device with beneficial agent matrix formed by a multi solvent system |
| JP2006028085A (ja) * | 2004-07-15 | 2006-02-02 | Shinshu Univ | 血中コレステロール濃度低下作用物質 |
| WO2006024547A2 (en) * | 2004-09-03 | 2006-03-09 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
| CN101098703B (zh) * | 2004-11-05 | 2011-08-03 | 费城儿童医院 | 用于分子治疗的生物降解连接剂 |
| EP1913155A4 (en) * | 2005-06-23 | 2009-08-12 | Univ British Columbia | COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION RELATING TO THE RESULTS AND RESPONSE OF A SUBJECT TO THERAPY |
| US20080004695A1 (en) * | 2006-06-28 | 2008-01-03 | Abbott Cardiovascular Systems Inc. | Everolimus/pimecrolimus-eluting implantable medical devices |
| WO2008091925A2 (en) * | 2007-01-23 | 2008-07-31 | Cook Incorporated | Treatment of aortic dissection or aneurysm |
| US20090104240A1 (en) * | 2007-10-19 | 2009-04-23 | Abbott Cardiovascular Systems Inc. | Dual Drug Formulations For Implantable Medical Devices For Treatment of Vascular Diseases |
| US8689439B2 (en) | 2010-08-06 | 2014-04-08 | Abbott Laboratories | Method for forming a tube for use with a pump delivery system |
| US8377000B2 (en) | 2010-10-01 | 2013-02-19 | Abbott Laboratories | Enteral feeding apparatus having a feeding set |
| US8377001B2 (en) | 2010-10-01 | 2013-02-19 | Abbott Laboratories | Feeding set for a peristaltic pump system |
| US11266496B2 (en) * | 2017-06-07 | 2022-03-08 | Shifamed Holdings, Llc | Adjustable optical power intraocular lenses |
| KR102136627B1 (ko) | 2018-07-09 | 2020-07-22 | 세종대학교산학협력단 | 리포좀을 포함하는 염증성 장질환 예방, 개선 또는 치료용 약학 조성물 및 건강기능식품 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786216A (en) * | 1987-11-17 | 1998-07-28 | Cytotherapeutics, Inc. | Inner-supported, biocompatible cell capsules |
| ATE126803T1 (de) * | 1989-11-09 | 1995-09-15 | Sandoz Ag | Heteroatome enthaltende tricyclische verbindungen. |
| US5352671A (en) * | 1989-11-09 | 1994-10-04 | Sandoz Ltd. | Heteroatoms-containing tricyclic compounds |
| WO1992015286A1 (en) * | 1991-02-27 | 1992-09-17 | Nova Pharmaceutical Corporation | Anti-infective and anti-inflammatory releasing systems for medical devices |
| WO1993000063A1 (en) * | 1991-06-28 | 1993-01-07 | Brown University Research Foundation | Capsule extrusion systems |
| AR004480A1 (es) * | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| GB9601120D0 (en) * | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| US5843172A (en) * | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
| US6153252A (en) * | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
| US6713119B2 (en) * | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
| JP4754714B2 (ja) * | 2000-06-01 | 2011-08-24 | テルモ株式会社 | 管腔内留置物 |
| WO2002026281A1 (en) * | 2000-09-29 | 2002-04-04 | Cordis Corporation | Coated medical devices |
| US20020082678A1 (en) * | 2000-12-22 | 2002-06-27 | Motasim Sirhan | Intravascular delivery of mizoribine |
| US6471980B2 (en) * | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
| US6939375B2 (en) * | 2000-12-22 | 2005-09-06 | Avantac Vascular Corporation | Apparatus and methods for controlled substance delivery from implanted prostheses |
| US20020082679A1 (en) * | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
| US20030033007A1 (en) * | 2000-12-22 | 2003-02-13 | Avantec Vascular Corporation | Methods and devices for delivery of therapeutic capable agents with variable release profile |
| US7018405B2 (en) * | 2000-12-22 | 2006-03-28 | Avantec Vascular Corporation | Intravascular delivery of methylprednisolone |
| ATE368482T1 (de) * | 2001-02-16 | 2007-08-15 | Abbott Lab Vascular Entpr Ltd | Implantate mit fk506 zur restenosebehandlung und -prophylaxe |
| JP2002239013A (ja) * | 2001-02-21 | 2002-08-27 | Terumo Corp | ステント及びその製造方法 |
| EP1389108A2 (en) * | 2001-05-09 | 2004-02-18 | Novartis AG | Methods for selective immunomodulation using pimecrolimus |
| EP1273314A1 (en) * | 2001-07-06 | 2003-01-08 | Terumo Kabushiki Kaisha | Stent |
| US20040234575A1 (en) * | 2002-05-09 | 2004-11-25 | Roland Horres | Medical products comprising a haemocompatible coating, production and use thereof |
-
2003
- 2003-11-14 RU RU2005118750/14A patent/RU2005118750A/ru not_active Application Discontinuation
- 2003-11-14 US US10/534,790 patent/US20060035879A1/en not_active Abandoned
- 2003-11-14 BR BR0316279-6A patent/BR0316279A/pt not_active IP Right Cessation
- 2003-11-14 WO PCT/EP2003/012737 patent/WO2004045578A2/en not_active Ceased
- 2003-11-14 KR KR1020057008673A patent/KR20050086648A/ko not_active Ceased
- 2003-11-14 NZ NZ539850A patent/NZ539850A/en active Application Revival
- 2003-11-14 EP EP03775353A patent/EP1585738A2/en not_active Withdrawn
- 2003-11-14 JP JP2004552593A patent/JP2006522007A/ja active Pending
- 2003-11-14 MX MXPA05005196A patent/MXPA05005196A/es unknown
- 2003-11-14 CN CNA2003801030061A patent/CN1714085A/zh active Pending
- 2003-11-14 PL PL03376169A patent/PL376169A1/xx not_active Application Discontinuation
- 2003-11-14 CA CA002511573A patent/CA2511573A1/en not_active Abandoned
- 2003-11-14 AU AU2003283399A patent/AU2003283399B2/en not_active Ceased
-
2005
- 2005-05-03 ZA ZA200503502A patent/ZA200503502B/en unknown
- 2005-05-10 EC EC2005005788A patent/ECSP055788A/es unknown
- 2005-05-24 CO CO05050163A patent/CO5690530A2/es not_active Application Discontinuation
- 2005-06-14 NO NO20052898A patent/NO20052898L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200503502B (en) | 2006-07-26 |
| AU2003283399A1 (en) | 2004-06-15 |
| BR0316279A (pt) | 2005-10-11 |
| CN1714085A (zh) | 2005-12-28 |
| ECSP055788A (es) | 2005-08-11 |
| US20060035879A1 (en) | 2006-02-16 |
| NO20052898L (no) | 2005-06-14 |
| CO5690530A2 (es) | 2006-10-31 |
| KR20050086648A (ko) | 2005-08-30 |
| AU2003283399B2 (en) | 2007-04-19 |
| WO2004045578A3 (en) | 2004-07-08 |
| CA2511573A1 (en) | 2004-06-03 |
| NZ539850A (en) | 2008-05-30 |
| WO2004045578A2 (en) | 2004-06-03 |
| JP2006522007A (ja) | 2006-09-28 |
| PL376169A1 (en) | 2005-12-27 |
| EP1585738A2 (en) | 2005-10-19 |
| MXPA05005196A (es) | 2005-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005118750A (ru) | Органические соединения | |
| Liu et al. | Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? | |
| Wang et al. | Effects of minocycline alone and in combination with mild hypothermia in embolic stroke | |
| Saliba Jr | Heparin in the treatment of burns: a review | |
| RU2008107255A (ru) | Системы введения лекарственных средств, содержащих рапамицин и его производные, которые предназначены для предупреждения и лечения сосудистых заболеваний | |
| RU2360646C2 (ru) | Эндолюминальный протез, содержащий лечебное средство | |
| CA2425696C (en) | Coated medical devices for the treatment of vascular disease | |
| JP2003501151A (ja) | 動脈再狭窄治療用装置および化合物 | |
| KR20040093058A (ko) | Ｎ-(5-(4-(4-메틸-피페라지노-메틸)-벤조일아미도-2-메틸페닐)-4-(3-피리딜)-2-피리미딘-아민 코팅된 스텐트 | |
| CA2408754A1 (en) | Delivery devices for treatment of vascular disease | |
| CN102091355A (zh) | 一种复合涂层冠脉药物洗脱支架及其制备方法 | |
| CN103110985A (zh) | 一种有多种药物的生物可降解支架 | |
| US20060013852A1 (en) | Use of organic compounds | |
| KR20070004795A (ko) | Ｖｅｇｆ 수용체 타이로신 키나제 억제제 코팅된 스텐트 | |
| Bartorelli et al. | Local heparin delivery prior to coronary stent implantation: acute and six‐month clinical and angiographic results | |
| US20080085293A1 (en) | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor | |
| CN106620897B (zh) | 一种抗再狭窄的管腔内支架材料 | |
| Zhang et al. | Local application of paeonol prevents early restenosis: a study with a rabbit vein graft model | |
| CN101496813A (zh) | 抗组织增生(血管再狭窄)组合物及应用方法 | |
| IT9086204A1 (it) | Metodo per la cura dell'impotenza erettiva maschile | |
| Nguyen et al. | Recent advances in microneedles for enhanced functional angiogenesis and vascular drug delivery | |
| Eton et al. | Enhanced cell therapy strategy to treat chronic limb-threatening ischemia | |
| Mirani et al. | The role of 10% sucralfate ointment in the reduction of acute postoperative pain after open hemorrhoidectomy | |
| RU2793516C1 (ru) | Способ ингибирования развития гиперплазии интимы в области дистального анастомоза в эксперименте на свиньях породы Крупная белая, мужского пола | |
| Baumbach et al. | Local delivery of a low molecular weight heparin following stent implantation in the pig coronary artery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090828 |